Faculty Of Medicine 10
451. Biological assays, electrochemical behavior, and theoretical DFT calculations of Ru(II) complexes of chiral phosphinite based based on β-amino alcohols: Transfer hyrogenation of ketones using a HCOOH/Et3N mixture
452. Cancer immunotherapy and cardiovascular side-effects: from treatment modalities to the use of the preventive effect of antihypertensive drugs
453. Investigating the Effect of Streptozotocin Induced Diabetes on the Ovarian Tissue of Nmri Mice Following the Injection of MgO and MgO NPs
454. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage The Global Burden of Disease Study 2021
455. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage The Global Burden of Disease Study 2021
456. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage The Global Burden of Disease Study 2021
457. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage The Global Burden of Disease Study 2021
458. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage The Global Burden of Disease Study 2021
459. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage The Global Burden of Disease Study 2021
460. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
461. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
462. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
463. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
464. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
465. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
466. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
467. MiR-186-5p inhibition restores synaptic transmission and neuronal network activity in a model of chronic stress
468. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): fourth Paediatric EUROMACS (Paedi-EUROMACS) report
469. Adolescents’ knowledge regarding Alzheimer’s disease is declining: An international study
470. SnO2:Au/Carbon Quantum Dots Nanocomposites: Synthesis, Characterization, and Antibacterial Activity
471. COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology
472. Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC
473. Insights into ancestral diversity in Parkinson’s disease risk: a comparative assessment of polygenic risk scores
474. Insights into ancestral diversity in Parkinson’s disease risk: a comparative assessment of polygenic risk scores
475. Interpretable Diagnosis of Pulmonary Emphysema on Low-Dose CT Using ResNet Embeddings
476. Demographic Characteristics and Treatment Outcomes of Intracranial Atherosclerosis Stenting: A Retrospective Case-Series of 216 Consecutive Patients
477. Global health at crossroads: uniting together to overcome challenges, restore trust and advance priorities for a sustainable future
478. Global health at crossroads: uniting together to overcome challenges, restore trust and advance priorities for a sustainable future
479. Global health at crossroads: uniting together to overcome challenges, restore trust and advance priorities for a sustainable future
480. Detection of enteric parasites and molecular characterization of Giardia duodenalis and Blastocystis sp. In patients admitted to hospital in Ankara, Turkey
481. How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC
482. How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC
483. Protective effect of dapagliflozin on lipopolysaccharide-induced acute lung injury via the SIRT-1/PGC-1α pathway
484. The Fear of COVID-19 Scale: Its Structure and Measurement Invariance Across 48 Countries
485. Mapping routine measles vaccination in low- and middle-income countries
486. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
487. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
488. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
489. Insights into the European heart failure epidemiology
490. Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction
491. The European heart failure management resources, treatment reimbursement and activities of professional and patient organizations
492. The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019
493. The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019
494. Antibiotic Resistance of Helicobacter pylori: Data from Central Asia
495. Association of IL-1β gene polymorphisms rs1143627, rs1799916, and rs16944 with altered risk of triple-negative breast cancer
496. Bioactive compounds from Prosopis species as potential oxidative stress and inflammation modulators: an update on mechanisms
497. Bioactive compounds from Prosopis species as potential oxidative stress and inflammation modulators: an update on mechanisms
498. Glycyrrhiza Genus: Enlightening Phytochemical Components for Pharmacological and Health-Promoting Abilities
499. Natural Coumarins: Exploring the Pharmacological Complexity and Underlying Molecular Mechanisms
500. Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy
1 8 9 10 11 12 14